Bio-Rad Laboratories Inc (BIO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bio-Rad Laboratories Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 325.50 $ — 85% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.7% failed
- More than 10% revenue growth is expected for the coming year 2.6% failed
- Share count grows by less than 3% a year -2.9% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 15.2% failed
- Gross margin at 40% or higher and without meaningful erosion 52.0% passed
- Goodwill from acquisitions does not grow faster than revenue 5.5% failed
- Net debt below twice EBITDA 12 m net cash passed
- Operating cash flow covers the profits of the last three years 3,084 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.7% failed
- Insiders hold at least 10% or are net buyers 16.3% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 8.8% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9.00 | 8.55 – 9.72 | 2,567 | -9.3% | 5 |
| 12/31/2027 | 9.72 | 8.75 – 11.32 | 2,635 | 8.0% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.34 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -25.57 | -310.70 | 668 | -2.00 | -107.20 | 124 | 81 |
| 2025: Q1 | 2.29 | -83.00 | 585 | -4.20 | 10.90 | 130 | 96 |
| 2025: Q2 | 11.67 | – | 652 | 2.10 | 48.80 | 117 | 71 |
| 2025: Q3 | -12.70 | -154.40 | 653 | 0.50 | -52.40 | 121 | 89 |
| 2025: Q4 | 26.65 | – | 693 | 3.90 | 103.90 | 165 | 119 |
| 2026: Q1 | -19.55 | -954.10 | 592 | 1.10 | -89.00 | 108 | 78 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,068 | 53 | 28 | 0.95 | 216 | 2,579 | 3,851 |
| 2017 | 2,160 | 117 | 115 | 3.82 | 104 | 2,930 | 4,273 |
| 2018 | 2,290 | -109 | 361 | 11.94 | 285 | 4,020 | 5,611 |
| 2019 | 2,312 | 230 | 1,759 | 58.27 | 458 | 5,755 | 8,009 |
| 2020 | 2,546 | 421 | 3,814 | 126.47 | 585 | 9,880 | 12,973 |
| 2021 | 2,923 | 500 | 4,254 | 140.83 | 657 | 13,685 | 17,799 |
| 2022 | 2,802 | 483 | -3,628 | -121.79 | 194 | 9,615 | 13,502 |
| 2023 | 2,671 | 338 | -637 | -21.82 | 375 | 8,741 | 12,299 |
| 2024 | 2,567 | 269 | -1,844 | -65.36 | 455 | 6,569 | 9,364 |
| 2025 | 2,583 | 271 | 760 | 27.85 | 532 | 7,454 | 10,577 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Bio-Rad Laboratories, Inc. entwickelt, fertigt und vertreibt Produkte für die Life-Science-Forschung und die klinische Diagnostik in den USA, Europa, Asien, Kanada, Lateinamerika und international.
| Employees | 7,450 |
|---|---|
| Headquarters | Hercules, CA |
| Address | 1000 Alfred Nobel Drive, 94547 Hercules, United States |
| Phone | 510 724 7000 |
| Website | bio-rad.com |
| IPO Date | 1. Jan 1966 |
| ISIN | US0905722072 |
| Stock Split | 2:1 on 03/08/2002 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Norman D. Schwartz | Chairman & CEO | 1950 |
| Jonathan P. DiVincenzo | President & COO | 1966 |
| Roop K. Lakkaraju CPA | Executive VP & CFO | 1971 |
| James J. Barry | Executive VP & President of Life Science Group | 1978 |
| Rajat Mehta | Executive Vice President of Global Commercial Operations | 1979 |
| Ruben Argueta | Vice President of Investor Relations | – |
| Matthew Werner | Senior VP and Chief Compliance & Privacy Officer | – |
| Courtney C. Enloe | Executive VP, General Counsel & Secretary | 1972 |
| Nanditha R. Yelamanchi | Executive Vice President of Global Human Resources | – |
| Michael Crowley | Executive Vice President of Global Commercial Operations | 1962 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 25. Jul 2026 | Engelhardt Eva Anette | EVP, President, CDG | Other | 89 | 314.46 | 27,987 |
| 25. Jul 2026 | Engelhardt Eva Anette | EVP, President, CDG | Other | 246 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.